findmyKOL

Michael Germain, MD

Enriched profile

RTANE Professor of Medicine, Tufts University School of Medicine; Medical Director of Renal Transplantation · Renal and Transplant Associates of New England (RTANE)

ORCIDNPI
Region🇺🇸 Springfield, MA · Northeast · United StatesSpecialtyNephrologyFocusESRD / Dialysis
Active KOLLatest publication2024Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Michael Germain is RTANE Professor of Medicine, Tufts University School of Medicine; Medical Director of Renal Transplantation at Renal and Transplant Associates of New England (RTANE). OpenAlex indexes 274 publications with 9,028 citations (h-index 50); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Michael J. Germain, MD, is RTANE Professor of Medicine, Tufts University School of Medicine at Renal and Transplant Associates of New England (RTANE), Springfield, MA. The public record shows 274 publications with 9,028 citations (h-index 50), centered on ESRD / Dialysis. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 30 companies.

  • Most recent indexed publication: 2024 · Nephrology, dialysis, transplantation
  • Top research focus: ESRD / Dialysis
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 30 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
ESRD / Dialysis1 trial

Research focus

OpenAlex concept fingerprint
ESRD / Dialysis

Drugs & molecules

across trials, industry payments and publications
Krystexxageneric · PegloticaseClinical trialsIndustry payments63PublicationsActhargeneric · CorticotropinClinical trialsIndustry payments55PublicationsTarpeyogeneric · BudesonideClinical trialsIndustry payments55Publications

Works with

trial sponsors and companies reporting payments
Horizon Therapeutics plcClinical trialsIndustry payments62AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments57Calliditas Therapeutics Us Inc.Clinical trialsIndustry payments55

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
274publications

Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.

9,028citations

Total citations across indexed works.

50h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
30companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

30 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    63.8%
    Calcium channel blocker16.9%
    Amlodipine Besylate91%Nifedipine Er9%
    Part D<11 patients
    Beta blocker10.9%
    Carvedilol61%Metoprolol Succinate39%
    Part D17 patients
  • Metabolism & gastrointestinal

    18.7%
    SGLT2 inhibitor15.3%
    Farxiga42%Jardiance32%Synjardy Xr15%Dapagliflozin11%
    Part D<11 patients
    Metabolic Alkalinizer2%
    Potassium Citrate Er100%
    Part D<11 patients
  • Nervous system

    5.2%
    Gabapentinoids3%
    Gabapentin100%
    Part D<11 patients
    SSRI2.2%
    Paroxetine Hcl100%
    Part D<11 patients
4 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B), 20230% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/cv/michael-germain-md-1

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Michael-Germain

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    University of Calgary Faculty of Medicine

    1976
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com
  • Board Certified

    American Board of Internal Medicine, Internal Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com
  • Board Certified

    American Board of Internal Medicine, Nephrology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record
  • Board member

    Renal Physicians Association (RPA), 2008–2014

    2014
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.